ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck, AstraZeneca Venture Stays Intact For At Least Two More Years

By Tess Stynes Merck & Co. (MRK) said AstraZeneca PLC (AZN.LN, AZN) won't exercise its option to acquire Merck's interest in their AstraZeneca L.P. partnership this year, putting any potential move off by two years. Under the amended agreement, AstraZeneca has a new option to acquire Merck's interest in June 2014, allowing Merck to record supply sales and equity income from the venture this year and next year as it aims to cope with the coming loss of market exclusivity for its blockbuster allergy and asthma drug Singulair. The amended accord is expected to add roughly three cents to five cents a share to Merck's earnings and about $200 million to revenue this year, though the company said it doesn't change its 2012 guidance. Chief Financial Officer Peter N. Kellogg said the amended pact provides clarity about the partnership and enhances Merck's ability to drive its performance through the impact of U.S. Singulair patent expiration later this year. Under the amended pact, the amount AstraZeneca would pay would be based on an agreed-upon value of Merck's interest in heartburn drugs Prilosec and Nexium--set at $327 million--and include a potential amount based on actual sales between any closing in 2014 and June 2018, as well as an exercise price that may factor in part of future sales of arthritis treatment Vimovo in the U.S., among other things. As a result of declining sales of Nexium and supply of bulk Nexium by third-party suppliers, Merck expects the drugs will make a lower quarterly contribution to earnings next year than during the fourth quarter of 2012. Merck plans to provide 2013 guidance when it reports its fourth-quarter earnings. Write to Tess Stynes at Tess.Stynes@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
02/04/201608:00:00FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) fo...
02/03/201616:13:00Merck Posts Lower Revenue and Profit -- 2nd Update
02/03/201616:09:00Correction to Merck Earnings Story
02/03/201613:08:00Merck Revenue and Profit Falls -- Update
02/03/201608:30:00Merck Revenue and Profit Falls
02/03/201608:21:00Merck Revenue and Profit Falls
02/03/201606:57:37Current Report Filing (8-k)
02/03/201606:45:00Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
01/28/201621:36:00FDA Approves Merck's New Hepatitis C Treatment -- 2nd Update
01/28/201620:15:00FDA Approves Merck's New Hepatitis C Treatment -- Update
01/28/201619:10:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00FDA Approves Merck's New Hepatitis C Treatment
01/28/201619:01:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) f...
01/28/201618:59:00Merck Receives FDA Approval of ZEPATIER™ (elbasvir & grazoprevir) f...
01/27/201613:49:00FDA to Review Merck Antitoxin for Clostridium Difficile
01/27/201608:30:00Merck Announces FDA Acceptance of Biologics License Application...
01/25/201605:00:00Affimed Enters into Collaboration with Merck to Evaluate AFM13...
01/19/201610:00:00Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal...
01/17/201621:30:00Samsung Gets European Approval for Enbrel Copy
01/16/201603:02:00Merck Pays $830 Million To Settle Suit Over Vioxx Claims

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad